This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Cystic fibrosis (CF); muscular dystrophy

Ribosome

In vitro studies have questioned the mechanism of action for ataluren (PTC124), which is in clinical development to treat CF and Duchenne muscular dystrophy (DMD). The proposed mechanism of action for ataluren is to induce readthrough of premature termination codons (PTCs) by ribosomes, thus increasing protein expression in genetic disorders for which PTCs cause disease. In a series of in vitro assays to measure PTC readthrough, ataluren had no effect, whereas the aminoglycoside antibiotic geneticin had a dose-dependent response. Next steps could include studies designed to further explore the mechanism of action for drugs thought to induce PTCs in vivo.
PTC Therapeutics Inc. has ataluren in Phase III testing to treat nonsense mutation DMD. Last year, the EMA accepted for review an MAA seeking conditional approval of ataluren to treat nonsense mutation DMD. The product also has completed a Phase III trial to treat nonsense mutation CF, with a confirmatory Phase III trial in the indication expected to start next year.

SciBX 6(29); doi:10.1038/scibx.2013.767
Published online Aug. 1, 2013

Patent and licensing status not applicable

McElroy, S.P. et al. PLoS Biol.; published online June 25, 2013;
doi:10.1371/journal.pbio.1001593
Contact: Stuart P. McElroy, University of Dundee, Dundee, U.K.
e-mail:
s.mcelroy@dundee.ac.uk